Citigroup’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Citigroup’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,500	Closed	-$28K	–	7766
2020 Q1	$28K	Sell	3,500 -18,300	-84%	-$276K	﹤0.01%	6469
2019 Q4	$451K	Buy	21,800 +9,400	+76%	+$159K	﹤0.01%	4505
2019 Q3	$170K	Buy	12,400 +4,600	+59%	+$54.6K	﹤0.01%	5275
2019 Q2	$96K	Buy	7,800 +7,600	+3,800%	+$87.7K	﹤0.01%	5921
2019 Q1	$2K	Sell	200 -4,800	-96%	-$64.1K	﹤0.01%	7550
2018 Q4	$57K	Buy	5,000 +1,500	+43%	+$23.5K	﹤0.01%	6134
2018 Q3	$65K	Buy	3,500 +3,000	+600%	+$68.9K	﹤0.01%	6298
2018 Q2	$13K	Sell	500 -1,400	-74%	-$36.3K	﹤0.01%	7102
2018 Q1	$43K	Buy	+1,900	New	+$46.4K	﹤0.01%	6286

Citigroup's FLXN Position: Q4 2021 in Review

Citigroup sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 23,901 shares — an estimated $146K sold.

Citigroup first reported a position in FLXN in Q1 2014 and held it in 31 quarters. The position peaked at $3.19M in Q4 2017. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

Citigroup reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
Citigroup sold 23,901 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $146K.
Citigroup first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and held it in 31 quarters.
Citigroup's Flexion Therapeutics, Inc. position peaked at $3.19M in Q4 2017.
1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Citigroup's 13F filing for Q4 2021, filed 10 Feb 2022.